Skip to main content
Open
Question
Forecasts
Track record
Unknowns
How it works
Sources
FAQ
Menu
← Evidence map
Article
Cancer discovery
2020
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma.
PubMed ↗
Publisher ↗
No numbers read from the abstract.
1 paper cites it
2020
2021
2022
2023
this paper
cites it
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma. | OpenQuestion